We’re attending the 2024 Mary Tyler Moore Vision Initiative Symposium on Curing Vision Loss from Diabetes this week where we will support their mission to end vision loss and blindness from diabetes.
BioCryst Pharmaceuticals, Inc.
生物技术研究
Durham，NC 34,393 位关注者
We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases.
关于我们
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world. As world leaders in structure-guided drug design, we draw on the strengths and expertise of all our colleagues—from those of us in the field or behind the scenes in our labs, to others based in home offices and around the globe. To view our LinkedIn community guidelines, please visit bit.ly/BCRXGuidelines.
- 网站
-
https://www.biocryst.com
BioCryst Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Durham，NC
- 类型
- 上市公司
- 创立
- 1986
- 领域
- Drug Discovery、Clinical Development、Rare Diseases、Regulatory Affairs和Product Commercialization
地点
BioCryst Pharmaceuticals, Inc.员工
动态
-
November is Diabetic Eye Disease Awareness Month. Diabetic eye disease, a leading cause of blindness, often has no early warning signs. That’s why it’s so important for people with diabetes to get regular eye exams to catch problems early — and get timely treatment and the right follow-up care. For more information visit https://lnkd.in/d2aQJp7
-
We are looking forward to attending the Sociedad Espa?ola de Alergología e Inmunología Clínica (SEAIC) International Symposium on Life-Threatening Allergic Diseases, where we will connect with the allergy community and learn about improving patient care.
-
-
November is #NationalFamilyCaregiversMonth, a time to recognize the incredible dedication and selflessness of family caregivers. For advice and support visit https://lnkd.in/dKPsx8y.
-
-
We enjoyed attending the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Boston, where we connected with the #HAE community and thought leaders in the allergy and immunology field.? #ACAAI24
-
-
Hereditary angioedema (HAE) is a very rare and potentially life-threatening genetic condition. HAE symptoms include episodes of edema (swelling) in various body parts including the hands, feet, face and airway. #ACAAI24
-
We’re looking forward to connecting with the #HAE community at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Scientific Meeting. Stop by our poster sessions to learn more. https://lnkd.in/gNNdPygt #ACAAI24
-
-
Last month we hosted patients and patient community leaders at our second annual Patient Community Open House at the BioCryst Discovery Center of Excellence in Birmingham, Alabama. The three-day program allowed us to listen to patient voices and share our commitment to keeping patients at the core of all we do.
-
-
Today is #WorldSightDay, which focuses the world’s attention on the importance of eye care. Diabetic Macular Edema (DME) is an eye condition occurring in people with diabetes that causes vision loss. #DiabeticMacularEdemaFacts #DMEFacts
-
We’re excited to announce that?our US Marketing Team won a gold #PM360TrailblazerAward for the ‘Life without Compromise’ campaign. Thank you PM360 Magazine for recognizing our hard work?to improve the lives of patients living with HAE.
-